BNP Paribas Exane downgraded Hologic (HOLX) to Neutral from Outperform with a $79 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX:
- Hologic’s Financial Health at Risk: Navigating Reimbursement and Guideline Challenges
- Hologic price target raised to $76 from $69 at Morgan Stanley
- Hologic Updates Restricted Stock Unit Award Agreement
- Cautious Hold Rating for Hologic Amid Strong Q4 Results and Future Uncertainties
- Hologic’s Mixed Performance and Acquisition Uncertainty Lead to Hold Rating